Leandro Cruz Hermida

Leandro Cruz Hermida

Auto-generated profile, based on publicly available information

Leandro Cruz Hermida

Cancer Data Science Laboratory (CDSL), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Cell
Verified
Journal Article
Closed access
PLPablo Landgraf
Pablo Landgraf
MRMirabela Rusu
Mirabela Rusu
RSRobert Sheridan
Robert Sheridan
ASAlain Sewer
Alain Sewer
NINicola Iovino
Nicola Iovino
TTThomas Tuschl
Thomas Tuschl

28 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
XMXiaotu Ma
Xiaotu Ma
YLYu Liu
Yu Liu
YLYanling Liu
Yanling Liu
LALudmil B. Alexandrov
Ludmil B. Alexandrov
MEMichael N. Edmonson
Michael N. Edmonson
JZJinghui Zhang
Jinghui Zhang
Analysis of molecular aberrations across multiple cancer types, known as pan-cancer analysis, identifies commonalities and differences in key biological processes that are dysregulated in cancer cells from diverse lineages. Pan-cancer analyses have been performed for adult1,2,3,4 but not paediatric cancers, which commonly occur in developing mesodermic rather than adult epithelial tissues5. Here we present a pan-cancer study of somatic alterations, including single nucleotide variants, small insertions or deletions, structural variations, copy number alterations, gene fusions and internal tandem duplications in 1,699 paediatric leukaemias and solid tumours across six histotypes, with whole-genome, whole-exome and transcriptome sequencing data processed under a uniform analytical framework. We report 142 driver genes in paediatric cancers, of which only 45% match those found in adult pan-cancer studies; copy number alterations and structural variants constituted the majority (62%) of events. Eleven genome-wide mutational signatures were identified, including one attributed to ultraviolet-light exposure in eight aneuploid leukaemias. Transcription of the mutant allele was detectable for 34% of protein-coding mutations, and 20% exhibited allele-specific expression. These data provide a comprehensive genomic architecture for paediatric cancers and emphasize the need for paediatric cancer-specific development of precision therapies.

11 December 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HBHamid Bolouri
Hamid Bolouri
JFJason E Farrar
Jason E Farrar
TTTimothy Triche
Timothy Triche
RRRhonda E Ries
Rhonda E Ries
ELEmilia L Lim
Emilia L Lim
SMSoheil Meshinchi
Soheil Meshinchi

17 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SKShelly Kalaora
Shelly Kalaora
ANAdi Nagler
Adi Nagler
DNDeborah Nejman
Deborah Nejman
MAMichal Alon
Michal Alon
CBChaya Barbolin
Chaya Barbolin
YSYardena Samuels
Yardena Samuels

12 September 2018 in Nature
Verified
Journal Article
Closed access
PDF file
TAThomas B Alexander
Thomas B Alexander
ZGZhaohui Gu
Zhaohui Gu
IIIlaria Iacobucci
Ilaria Iacobucci
KDKirsten Dickerson
Kirsten Dickerson
JCJohn K. Choi
John K. Choi
CMCharles G Mullighan
Charles G Mullighan

21 August 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SGSamantha Gadd
Samantha Gadd
VHVicki Huff
Vicki Huff
AWAmy L Walz
Amy L Walz
AOAriadne H A G Ooms
Ariadne H A G Ooms
AAAmy E Armstrong
Amy E Armstrong
EPElizabeth J Perlman
Elizabeth J Perlman
Elizabeth Perlman and colleagues use genome-wide sequencing, RNA expression, DNA copy number and methylation analyses to characterize the genomic landscape of Wilms tumors. Their integrated analyses implicate two major classes of genetic changes in Wilms tumors that preserve the progenitor state and/or interrupt normal kidney development. We performed genome-wide sequencing and analyzed mRNA and miRNA expression, DNA copy number, and DNA methylation in 117 Wilms tumors, followed by targeted sequencing of 651 Wilms tumors. In addition to genes previously implicated in Wilms tumors (WT1, CTNNB1, AMER1, DROSHA, DGCR8, XPO5, DICER1, SIX1, SIX2, MLLT1, MYCN, and TP53), we identified mutations in genes not previously recognized as recurrently involved in Wilms tumors, the most frequent being BCOR, BCORL1, NONO, MAX, COL6A3, ASXL1, MAP3K4, and ARID1A. DNA copy number changes resulted in recurrent 1q gain, MYCN amplification, LIN28B gain, and MIRLET7A loss. Unexpected germline variants involved PALB2 and CHEK2. Integrated analyses support two major classes of genetic changes that preserve the progenitor state and/or interrupt normal development.